Maa: Australia
Kieli: englanti
Lähde: APVMA (Australian Pesticides and Veterinary Medicines Authority)
PIMOBENDAN
DECHRA VETERINARY PRODUCTS (AUSTRALIA) PTY. LTD.
ORAL SOLUTION/SUSPENSION
PIMOBENDAN PYRIDAZINONE Active 1.5 mg/ml
25 mL
VM - Veterinary Medicine
CARDIOVASCULAR SYSTEM
Poison schedule: 4; Withholding period: ; Host/pest details: DOG: [CONGESTIVE HEART FAILURE]
Registered
2023-07-01
Product Name: APVMA Approval No: Cardisure Oral Solution 84375/110276 Label Name: Cardisure Oral Solution Signal Headings: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY READ SAFETY DIRECTIONS Constituent Statements: 1.5 mg/mL PIMOBENDAN Claims: For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation) Net Contents: 25 mL Directions for Use: Read the enclosed leaflet before using this product Restraints: Contraindications: This product is contraindicated for use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). Precautions: Cardisure Oral Solution should only be administered to pregnant and lactating bitches if the expected therapeutic benefits outweigh the potential risk. Studies into the effect of pimobendan on the reproductive function of male doges have not been conducted. The use in dogs not showing signs of cardiac disease is not recommended. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. The pimobendan induced increase in contractility of the heart RLP APPROVED is attenuated in the presence of the calcium antagonist verapamil and the B-antagonist propranolol. Side Effects: A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and can be avoided by reducing the dose in those cases. In rare cases transient diarrhoea, anorexia or lethargy have been observed. Dosage and Administration: Shake well before use. Cardisure Oral Solution should be administered orally at a dose range of 0.1 mg to 0.3 mg pimobendan/kg bodyweight twice daily. The ideal dose is 0.25 mg pimobendan/kg body weight (equivalent to 0.167 mL Cardisure Oral Solution/kg bodyweight) twice daily administered approximately 12 hours apart. Each dose should be Lue koko asiakirja